Navigation Links
ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
Date:1/23/2008

-up at our plant on Isle of Man and will remain on target for completion of the final phase of the development program in June 2008."

The PRDT prion removal technology is presently being used in the P-Capt (R) prion filter, CE marked in September 2006, and marketed by MacoPharma for the elimination of Transmissible Spongiform Encephalopathies ("TSEs") such as vCJD in red blood cell concentrates.

"ProMetic is extremely excited about the progress of this product. This new use represents an extension of the PRDT prion capture technology platform into the plasma and plasma fractionation industry and we trust this will culminate in introduction of our first prion reduction product for the biopharmaceutical industry in 2008," commented Pierre Laurin, President and Chief Executive Officer of ProMetic.

Notes for Editors

About Variant Creutzfeldt-Jakob Disease

Variant Creutzfeldt-Jakob disease ("vCJD") is characterized by the accumulation of large deposits in the brain and the nervous system of the misfolded prion protein. The resulting damage causes sponge-like holes to appear in the brain causing a fatal degenerative CNS disorder. Such abnormal prion proteins may be sufficient to transmit the disease. It is now thought that all the population is susceptible to vCJD, irrespective of genetic make-up. vCJD was initially transmitted to humans by the consumption of BSE contaminated meat, but a secondary route of transmission by the transfusion of blood units from asymptomatic vCJD individuals threatens to increase the prevalence of the fatal disease. Although the first incidence of vCJD appears to have peaked, scientists still remain concerned over the potential of a second longer incubation and bigger peak and caution vigilance. Recent scientific research estimates that there are 3,800 asymptomatic vCJD carriers in the UK at a minimum and the 2006 National CJD Surveillance Unit report stated that "the incidence of vCJD may increase agai
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. Vapotherm(R) Announces Validation of U.S. Patent
3. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
4. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
5. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
6. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
7. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
8. Peptimmune Announces First Close of Series D Private Financing
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
11. Vasogen Announces 2007 Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2010)... US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1).  Additional claims cover ... ... , ... ... ...
(Date:3/11/2010)... for Advanced Micro Nano Technology Products (ACAMP) hosts Conventional Energy seminar , ... , ... ... ... EDMONTON , March 11 /PRNewswire/ - Today at ACAMP,s latest seminar, ...
(Date:3/11/2010)... 11 Advanced Life Sciences ... biopharmaceutical company engaged in the discovery, development ... therapeutic areas of infection, oncology and respiratory ... and Drug Administration (FDA) has provided guidance ... the approvability of Restanza™ (cethromycin), a novel ...
(Date:3/10/2010)... plants is the most important technological innovation during ... has occurred as humans have used individuals carrying ... current issue of Nature an international ... revealed some of the secrets underlying the remarkable ... chicken has in recent years become the most ...
Breaking Biology Technology:Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage 2Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage 3Alberta companies delivering new products to the Conventional Energy marketplace 2Alberta companies delivering new products to the Conventional Energy marketplace 3Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 2Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 3Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 4Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 5Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 6Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 7Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 8Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 9Scientific breakthrough in genetic studies of animal domestication 2
... NuVasive, Inc. (Nasdaq:,NUVA), a medical device company focused on ... announced today,details relating to its second quarter 2008 earnings ... after the close of the market., NuVasive will ... at 5:30,p.m. ET / 2:30 p.m. PT to discuss ...
... Insmed Inc.,(Nasdaq CM: INSM), a developer of follow-on ... that the,Company has retained the services of RBC ... advisor., "Insmed,s Board of Directors and senior ... will be utilizing RBC,s experience and,expertise to examine ...
... today announced that it will report financial results for ... July 24, 2008 after the,close of the market., ... p.m. Pacific,Time on Thursday, July 24, 2008 to discuss ... website at http://www.cepheid.com/investors ,at least 15 minutes before ...
Other Biology Technology:NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results 2NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results 3Insmed Retains RBC Capital Markets as Strategic Financial Advisor 2Insmed Retains RBC Capital Markets as Strategic Financial Advisor 3Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast 2
(Date:3/15/2010)... (March 15, 2010) -- The popular forage and turf grass ... the U.S. -- an area that,s estimated to be larger ... by ecologists at Rice University and Indiana University suggests there ... of the six-year study, which are available online in the ... fungus living inside fescue can have far-reaching effects on plant, ...
(Date:3/15/2010)... discovery, Plasmodium vivax ( P. vivax ) ... to be resistant to the disease, those who do ... red blood cells, according to researchers from Case Western ... Madagascar Ministry of Health. In a study of more ... malaria transmission areas of Madagascar, the researchers found that ...
(Date:3/15/2010)... begin each day with a cup of steaming ... as "the devil,s brew," coffee contains several nutrients ... biologically active compounds (eg, polyphenols) that may promote ... beneficial link between coffee consumption and type 2 ... causative, however, requires controlled intervention trials. Two articles ...
Breaking Biology News(10 mins):Study: Grass, fungus combination affects ecology 2Duffy-negative blood types no longer protected from P. Vivax malaria 2Duffy-negative blood types no longer protected from P. Vivax malaria 3New Disability Income Insurance Options Provide More Choice for Californias Small Business Owners 62558 1New Disability Income Insurance Options Provide More Choice for Californias Small Business Owners 62558 2New Disability Income Insurance Options Provide More Choice for Californias Small Business Owners 62558 3New Disability Income Insurance Options Provide More Choice for Californias Small Business Owners 62558 4Southern Tier HealthLink NY Selects InterComponentWare to Deliver Core Components of HIE 62554 1Southern Tier HealthLink NY Selects InterComponentWare to Deliver Core Components of HIE 62554 2Researchers identify gene that spurs deadly brain cancer 62553 1Researchers identify gene that spurs deadly brain cancer 62553 2Researchers identify gene that spurs deadly brain cancer 62553 3
... or rice research, very few of Asia's best and brightest ... that has been a foundation of the Asian way of ... be rice farmers, and even fewer young Asians are choosing ... region. , However, an innovative project being launched this ...
... than 25 million people in sub-Saharan Africa, according to ... vaccine against the virus have achieved limited success. But ... found widely in that region of Africa ?chancroid ?was ... HIV as much as 10-fold? , That may be ...
... new mechanism used by cells ?and manipulated by retroviruses ?to ... in cancer. , The mechanism uses an enzyme called ... , The study by researchers with The Ohio State ... Richard J. Solove Research Institute and the OSU College of ...
Other Biology News:A rice future for Asia 2Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3Scientists discover new regulating mechanism in cells 2Scientists discover new regulating mechanism in cells 3
MAB3246 recognizes the neuro-endocrine specific protein (NSP) C....
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: